Cargando…
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
SIMPLE SUMMARY: H3K27M-mutant diffuse midline glioma is a rare childhood cancer originating in midline brain structures. The H3K27M mutation substitutes an amino acid on histone H3 that promotes gene expression and tumor growth. This cancer has a dismal prognosis and requires new and better treatmen...
Autores principales: | Argersinger, Davis P., Rivas, Sarah R., Shah, Ashish H., Jackson, Sadhana, Heiss, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582453/ https://www.ncbi.nlm.nih.gov/pubmed/34771443 http://dx.doi.org/10.3390/cancers13215280 |
Ejemplares similares
-
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
por: Banan, Rouzbeh, et al.
Publicado: (2017) -
MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
por: Zhao, Ji-ping, et al.
Publicado: (2022) -
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022) -
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020) -
Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)